Results 211 to 220 of about 2,059,114 (391)
YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy +9 more
wiley +1 more source
Influential factors shaping consumers' green packaging purchase intentions. [PDF]
Wang J, Li G, Luh DB.
europepmc +1 more source
Radioactive waste package acceptance criteria
E.L. Moore, D. B. Calmus
openalex +2 more sources
Replication package for: "Corruption and firm growth: evidence from around the world"
Raymond Fisman +3 more
openalex +1 more source
Emerging role of ARHGAP29 in melanoma cell phenotype switching
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster +3 more
wiley +1 more source
Advances and Challenges in Smart Packaging Technologies for the Food Industry: Trends, Applications, and Sustainability Considerations. [PDF]
Davidescu MA +7 more
europepmc +1 more source
The role of packaging in minimising food waste in the supply chain of the future [PDF]
This report focuses on packaging opportunities that may help to reduce or recover food waste, proposes opportunities for industry to address food waste through innovative and sustainable primary, secondary and tertiary packaging.
core
Optimization of Returnable Packaging Flows Planning
Maria Manuel Pires Afonso dos Santos
openalex +2 more sources
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern +7 more
wiley +1 more source

